Study details
Enrolling now
Treat-to-Target Endoscopic Remission in IBD Patients
University of California, San Diego
NCT IDNCT05230173ClinicalTrials.gov data as of Apr 2026
Target enrollment
250
Study length
about 5.7 years
Ages
18+
Locations
22 sites in CA, CO, CT +12
About this study
This trial is testing whether switching to a different targeted immunomodulator (TIM) therapy, aiming for endoscopic remission, is more effective than continuing the current TIM in people with inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis, who are currently in symptomatic remission but have moderate to severe inflammation on endoscopy.
Based on ClinicalTrials.gov records.
What participants do
- 1.Pragmatic
Primary goalTime to Treatment Failure
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Time to Treatment Failure
Secondary: Overall Quality of Life
Body systems
Gastroenterology